These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 15152944

  • 1. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer.
    O'Connor R, Heenan M, Connolly L, Larkin A, Clynes M.
    Anticancer Res; 2004; 24(2A):457-64. PubMed ID: 15152944
    [Abstract] [Full Text] [Related]

  • 2. Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model.
    Su CC, Yang JS, Lu CC, Chiang JH, Wu CL, Lin JJ, Lai KC, Hsia TC, Lu HF, Fan MJ, Chung JG.
    Phytother Res; 2010 Feb; 24(2):189-92. PubMed ID: 20077433
    [Abstract] [Full Text] [Related]

  • 3. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M, Benzo A, Irrissuto C, Lopez G, Curatella B, Maggi CA, Manzini S, Crea A, Caroli S, Cubadda F, Binaschi M.
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [Abstract] [Full Text] [Related]

  • 4. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC, Huang RC.
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
    Zhu X, Sui M, Fan W.
    Anticancer Res; 2005 Nov; 25(3B):1953-62. PubMed ID: 16158930
    [Abstract] [Full Text] [Related]

  • 6. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
    O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J.
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):79-87. PubMed ID: 16642371
    [Abstract] [Full Text] [Related]

  • 7. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
    Peer D, Dekel Y, Melikhov D, Margalit R.
    Cancer Res; 2004 Oct 15; 64(20):7562-9. PubMed ID: 15492283
    [Abstract] [Full Text] [Related]

  • 8. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
    Lelong-Rebel I, Brisson C, Fabre M, Bergerat JP, Rebel G.
    Anticancer Res; 2008 Oct 15; 28(1A):55-68. PubMed ID: 18383825
    [Abstract] [Full Text] [Related]

  • 9. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
    Fang W, Li Y, Cai Y, Kang K, Yan F, Liu G, Huang W.
    J Pharm Pharmacol; 2007 Dec 15; 59(12):1649-55. PubMed ID: 18053326
    [Abstract] [Full Text] [Related]

  • 10. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A.
    Cancer Res; 2004 Jul 15; 64(14):4900-5. PubMed ID: 15256461
    [Abstract] [Full Text] [Related]

  • 11. Dibenzocyclooctadiene lignans overcome drug resistance in lung cancer cells--study of structure-activity relationship.
    Slaninová I, Brezinová L, Koubíková L, Slanina J.
    Toxicol In Vitro; 2009 Sep 15; 23(6):1047-54. PubMed ID: 19531378
    [Abstract] [Full Text] [Related]

  • 12. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.
    Guichard SM, Else R, Reid E, Zeitlin B, Aird R, Muir M, Dodds M, Fiebig H, Sadler PJ, Jodrell DI.
    Biochem Pharmacol; 2006 Feb 14; 71(4):408-15. PubMed ID: 16360645
    [Abstract] [Full Text] [Related]

  • 13. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
    McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Pérez-Soler R, Horwitz SB.
    Cancer Res; 2005 Apr 01; 65(7):2854-60. PubMed ID: 15805287
    [Abstract] [Full Text] [Related]

  • 14. Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma.
    Budak-Alpdogan T, Chen B, Warrier A, Medina DJ, Moore D, Bertino JR.
    Clin Cancer Res; 2009 Feb 15; 15(4):1232-40. PubMed ID: 19174488
    [Abstract] [Full Text] [Related]

  • 15. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
    Yen WC, Lamph WW.
    Prostate; 2006 Feb 15; 66(3):305-16. PubMed ID: 16245282
    [Abstract] [Full Text] [Related]

  • 16. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
    Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R.
    Clin Cancer Res; 2004 Dec 15; 10(24):8641-7. PubMed ID: 15623648
    [Abstract] [Full Text] [Related]

  • 17. Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums.
    Khokhar NZ, She Y, Rusch VW, Sirotnak FM.
    Clin Cancer Res; 2001 Oct 15; 7(10):3199-205. PubMed ID: 11595715
    [Abstract] [Full Text] [Related]

  • 18. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.
    Gandhi L, Harding MW, Neubauer M, Langer CJ, Moore M, Ross HJ, Johnson BE, Lynch TJ.
    Cancer; 2007 Mar 01; 109(5):924-32. PubMed ID: 17285598
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM.
    Cancer Chemother Pharmacol; 2008 Nov 01; 62(6):1045-54. PubMed ID: 18301895
    [Abstract] [Full Text] [Related]

  • 20. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ, Tian H, Joseph IB, Menon K, Frost D.
    Cancer Chemother Pharmacol; 2007 May 01; 59(6):725-32. PubMed ID: 16967299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.